Research
Hormonal
Soy isoflavone supplementation improves insulin sensitivity and reduces fasting insulin levels in postmenopausal women, particularly those with metabolic syndrome or hyperinsulinemia.
Postmenopausal women, especially those with metabolic syndrome, may benefit from soy isoflavone supplementation (around 54mg/day) to improve insulin sensitivity and lower fasting insulin levels.
GoodSupportsHIGH confidence
Among published clinical trials, a research group from Italy has carried out several studies monitoring cardiovascular risk factors in women receiving 54 mg of genistein. After a 6-month intervention in 60 healthy women, a decrease in insulin and insulin resistance was observed [110].
Why this rating
Supported by multiple RCTs showing consistent improvements in insulin sensitivity in specific subgroups.
Source
Effects of Dietary Phytoestrogens on Hormones throughout a Human Lifespan: A Review
Inés Domínguez‐López et al. · Nutrients · 2020
DOI 10.3390/nu12082456
narrative_reviewCited 182×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Dietary phytoestrogens (specifically soy isoflavones) do not significantly alter circulating testosterone, free testosterone, or estradiol levels in healthy adult men, refuting concerns that soy intake causes feminization or hypogonadism.Good
- Soy isoflavones can induce goitrogenic effects in individuals with pre-existing hypothyroidism or iodine deficiency, potentially advancing subclinical hypothyroidism to overt hypothyroidism.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →